Abstract Details

Title Observational, retrospective study in relapsing-remitting multiple sclerosis to compare the effectiveness of second line treatments Fingolimod and Natalizumab in Spanish clinical practice

Topic Multiple Sclerosis

Presentation(s) P1 - (-)

Poster/Presentation
Number 358

Background

Objective

Design/Methods

Results

Conclusions

Authors/Disclosures
Francisco Javier Ricart PRESENTER	Francisco Javier Ricart has received personal compensation for serving as an employee of Novartis. Francisco Javier Ricart has received personal compensation for serving as an employee of Novartis.
Carmen Duran Herrera (Grupo 7 Viajes)	No disclosure on file
Sergio Martinez-Yelamos, MD	No disclosure on file
Teresa Ayuso, MD (Hospital de Navarra)	No disclosure on file
Miguel Angel Hernandez Perez (Hospital Nuestra Senora de Candelaria)	Miguel Angel Hernandez Perez has nothing to disclose.
	No disclosure on file
Angel P. Sempere, MD	Dr. Sempere has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Roche. Dr. Sempere has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Biogen. Dr. Sempere has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Merck.
	No disclosure on file
Jose Meca Lallana, MD (Hospital Clinico Universitario Virgen De La Arrixaca)	Dr. Meca Lallana has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Merck. Dr. Meca Lallana has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Dr. Meca Lallana has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sanofi. Dr. Meca Lallana has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sandoz. Dr. Meca Lallana has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Janssen. Dr. Meca Lallana has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Bristol Myers Squibb. Dr. Meca Lallana has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen. Dr. Meca Lallana has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Biogen. Dr. Meca Lallana has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Bristol-Myers-Squibb. Dr. Meca Lallana has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Merck. Dr. Meca Lallana has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Novartis. Dr. Meca Lallana has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Roche. Dr. Meca Lallana has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Sanofi. The institution of Dr. Meca Lallana has received research support from Merck. The institution of Dr. Meca Lallana has received research support from Novartis. The institution of Dr. Meca Lallana has received research support from Roche. The institution of Dr. Meca Lallana has received research support from Sanofi. The institution of Dr. Meca Lallana has received research support from Biogen.